Good leaders in the biosciences share multiple characteristics, starting with certain personality traits – some that are particularly unique and important to the bioscience sector. They also understand certain concepts, which are necessary for bioscience companies to be successful.
Using an effectuation theory lens, we study reverse stock splits in the biotech industry where significant uncertainty makes specific scenarios of success difficult to predict. We conjecture and find that, in contrast to other environments where there is less uncertainty, reverse stock splits in the biotech industry are followed by positive abnormal returns over the subsequent 1- to 12-months. Also consistent with our effectuation-based predictions, we find that these returns are positively related to the reverse split ratio, size, cash holding, and long-term debt, and negatively related to the market-to-book ratio and firm age. We also find that liquidity increases after a reverse stock split. These results suggest that the concept of effectuation theory is better suited to analyzing reverse stock splits in the biotech industry.
Reverse Stock Splits in the Biotechnology Industry: An Effectuation Approach Read Post »
The paper presents the limited quantitative and qualitative analysis of the biotechnology and ICT industries in Lithuania and Estonia, as well as public policy instruments aimed at supporting the development of these industries. In depth analysis of th…
Differentiating Public Policy for Technology Startups – Essential for Biotech? Read Post »
In recent years cell therapies have evolved and matured, moving from academia to industry. Scale up of a process is the natural path of any product evolutionary development and maturation, this process not only allows higher manufacturing capacity to meet demands but rather to increases the yields and reduces cost of goods. Cells are living things that react to the environment and conditions in which they grow, therefore process changes should be done as early as possible. The traditional 2D culturing systems can be truly up scaled, therefore there is a need to advance to bioreactors that will influence the product. Additionally, in order to make cell therapy a viable one, the cost of manufacturing is critical. Cost drivers such as media, serum, footprint, human resource and infrastructure must be optimized without changing the cells critical quality attributes. The paper analyze the main cost drivers on the cost of goods and is based on the experience of cell manufacturing in both traditional 2D and three dimensional (3D) bioreactor systems produced in Pluristem therapeutics GMP site. Furthermore, the paper discussed possible process development steps to insure cost efficiency emphasizing the need and benefit of early process development investment.
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Patenting human genes and mutations: A personal perspective
Go to paperABSTRACT:
The Journal of Commercial Biotechnology is a unique forum for all thos…
Patenting human genes and mutations: A personal perspective Read Post »
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
ABSTRACT: The recent approval of a follow-on version of Pfizer’s Genotropin (recombinant human growth hormone) signalled the beginning of the end of an era in which biopharmaceuticals enjoyed immunity from competition even after expiration of their patent protection. This paper describes many of the key scientific challenges facing the nascent ‘biogenerics’ industry and the evolving regulatory framework that will shape its competition with innovator companies…
The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.
Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:
For more information, see the Journal of Commercial Biotechnology website
As an offshoot of PatentStat, I’ve assembled a set of graphs of patent inventor locations, focusing in 33 industry sectors.
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
ABSTRACT: This paper analyses the recent ruling in Kinik Co. v. Int’l Trade Comm’n, 362 F.3d 1359 (Fed. Cir. 2004), and the impact that decision may have on proceedings before the US International Trade Commission under the Tariff Act of 1930 (19 USC §1337(a)) – particularly those concerning the importation of products derived from practising US patented processes abroad.
The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.
Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:
For more information, see the Journal of Commercial Biotechnology website
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
The regulatory system in the EU and further afield
Go to paperABSTRACT: The regulation of modern biotechnology began almost as soon as the potential ben…
The regulatory system in the EU and further afield Read Post »
This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s